Safety and Efficacy of Liraglutide in Parkinson's Disease
Parkinson Disease
About this trial
This is an interventional treatment trial for Parkinson Disease focused on measuring Parkinson's Disease, Liraglutide, Antidiabetic agents, GLP-1 agonists, Insulin resistance
Eligibility Criteria
Inclusion Criteria:
- Diagnosis of idiopathic PD according to the United Kingdom Parkinson's Disease Society Brain Bank (UKPDSBB) criteria for at least 2 years
- Responsive to levodopa or dopaminergic treatment
Male or female between 25 and 85 years of age at time of enrollment
- Women of child-bearing potential (WOCBP) must agree to use a reliable method of contraception (e.g., oral contraceptive or long-term injectable or implantable hormonal contraceptive, double barrier methods (such as condom plus diaphragm, condom plus spermicide foam, condom plus sponge), or intra-uterine devices) throughout the duration of the trial period and must have a negative serum pregnancy test at screening
- Male patients with female partners who have child bearing potential must agree to use adequate contraception throughout the duration of the trial period
- Capacity to give informed consent
- Ability to self-administer, or to arrange a care partner to administer trial drug, to comply with trial protocol, and to attend necessary clinic visits off medication
Exclusion Criteria:
- Diagnosis or suspicion of other causes for Parkinsonism, including drug- or toxin-induced parkinsonism and other neurodegenerative conditions, including multiple system atrophy, progressive supranuclear palsy, Huntington's disease, Wilson's disease, or Alzheimer's disease
- Active treatment with anticholinergic medications (e.g., trihexyphenidyl, tricyclic antidepressants)
- Known abnormality on CT or MRI brain imaging considered to cause symptoms or signs of neurological dysfunction, or considered likely to compromise compliance with trial protocol
- Concurrent dementia defined by a score lower than 120 on the MADRS-2 and/or inability to complete scale per neuropsychologist discretion
- Concurrent severe depression defined by a score greater than 29 on the Beck Depression Inventory
- Prior intracerebral surgical intervention for PD, including deep brain stimulation, lesional surgery, growth factor administration, gene therapy, or cell transplant
- Already actively participating in a trial of a device, drug, or surgical treatment for PD, or trial participation within 30 days prior to the baseline visit
- Diagnosis of diabetes mellitus of any type, established historically or by:
- Fasting plasma glucose levels equal or above 126 mg/dl
- Hemoglobin A1c equal or above 6.5%
- Active treatment with oral antidiabetic medications
- History of severe cardiac disease (e.g., angina, myocardial infarction, or cardiac surgery) in the preceding year
Significant systemic illness likely to result in deterioration of the patient's condition or, in the Investigator's opinion, affect the patient's safety during the study, including in particular:
- History of pancreatitis
- Personal or family history of medullary thyroid carcinoma
- History of multiple endocrine neoplasia syndrome type 2
- History of alcoholism
- Severe gastrointestinal disease, including gastroparesis
- Treatment with immunosuppressive medications (e.g., systemic corticosteroids) within the last 90 days or chemotherapeutic agents for malignancy within the last 2 years
- Severe renal insufficiency (CrCl <30)
- Moderate or severe hepatic impairment
- Severe hypertriglyceridemia (triglycerides >500 mg/dl)
- Females who are pregnant or breast feeding
- Prior serious hypersensitivity reaction to Victoza or any of the product components 10) Body Mass Index <18.5
Sites / Locations
- Cedars Sinai Medical Center
Arms of the Study
Arm 1
Arm 2
Active Comparator
Placebo Comparator
Liraglutide
Placebo
Liraglutide 6 mg/ml (Novo Nordisk A/S) will be self-administered subcutaneously once daily at a maximum dose of 1.8 mg after a 2 week titration schedule.
Placebo will be self-administered subcutaneously once daily according to the same schedule.